JUVAZIN- elastomer, silicone, for scar management Misemer Pharmaceutical

Juvazin

INGREDIENTS

Dimethicone, Dimethicone Crosspolymer, Trimethylsiloxysilicate.

INDICATIONS AND USES

JuvazinTM is intended for the management of old and new scars, including hypertrophic and keloid scars, resulting from general surgical procedures, trauma, wounds and burns.

WARNINGS

Avoid direct contact with eyes, mucous membranes, third degree burns and open wounds. JuvazinTM should not be used on dermatological conditions that disrupt the integrity of the skin. For external use only. If irritation occurs, discontinue use and consult your physician.

Keep this product out of the reach of children.

Store below 25°C/77°F.

PRECAUTIONS


Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner.


CALL YOUR DOCTOR ABOUT SIDE EFFECTS.


Call your doctor about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

DOSAGE AND ADMINISTRATION

Ensure that the affected area is clean and dry. Apply JuvazinTM to the area as a very thin coat and allow to dry. Apply JuvazinTM twice daily. Once dry, JuvazinTM can be covered with cosmetics or sunscreen. Recommended duration of treatment 60-90 days.







JUVAZIN

elastomer, silicone, for scar management

Product Information

Product Type MEDICAL DEVICE Item Code (Source) NHRIC:0276-0600

Inactive Ingredients			
Ingredient Name	Strength		
TRIMETHYLSILOXYSILICATE (M/Q 0.6-0.8) (UNII: 5041RX63GN)			
DIMETHICONE CROSSPOLYMER (450000 MPA.S AT 12% IN CYCLOPENTASILOXANE) (UNII: UF7620L1W6)			
DIMETHICONE (UNII: 92RU3N3Y1O)			

Packaging						
	#	Item Code	Package Description	Marketing Start Date	Marketing End Date	
	1	NHRIC:0276-0600- 30	30 in 1 TUBE; Type 0: Not a Combination Product			

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
exempt device	MDA	12/01/2021	

Labeler - Misemer Pharmaceutical (784121365)

Revised: 7/2019 Misemer Pharmaceutical